Plan Your Financial Future in Minutes
Use our free SIP Calculator to estimate your investment returns, visualize compounding, and start building wealth today — no sign-up required.
Why Use Our SIP Calculator?
Simple Inputs
Just enter your monthly investment, time period, and expected return rate.
Visual Growth Charts
See how your wealth grows month by month with powerful visuals.
Customizable Results
Test different scenarios to find the perfect investment plan for you.
How I Turned ₹5,000/month into ₹6 Lakhs — My 3-Year SIP Journey
In 2020, I was saving ₹5,000/month with no real strategy. I stumbled into SIPs by chance. Today, that same habit has grown into ₹6,12,000 — and taught me 3 major lessons about compounding, patience, and mistakes I wish I avoided earlier.
📉 What Went Wrong in Year 1
In my first year, I panicked during a market dip and pulled out my SIP investments. That single move cost me potential gains and broke the compounding chain. I learned the hard way that reacting emotionally to market swings is a recipe for regret.
📈 Lesson Learned: Consistency Beats Timing
- Missed rallies by being out of the market
- Lost out on rupee cost averaging
- Peace of mind improved with automation and discipline
🔄 My Portfolio Before vs After
Before (2020)
- Random savings in bank account
- No real investment plan
- Low returns (2-3% p.a.)
After (2023)
- Disciplined SIPs in diverse mutual funds
- Portfolio value: ₹6,12,000
- Average returns: 13-15% p.a.
🧠 What I’d Do Differently If Starting Again
If I could start over, I’d set up my SIPs and forget about the daily market noise. I’d diversify a bit more, avoid panic-selling, and trust the process. Most importantly, I’d start even earlier — because time is your biggest ally in compounding.
COPENHAGEN: Denmark’s Novo Nordisk on Monday stated it has agreed to purchase Cardior Prescription drugs for as much as 1.03 billion euros ($1.11 billion) to strengthen its cardiovascular pipeline. The acquisition is according to the Danish drugmaker’s goal to increase its concentrate on diabetes and weight-loss therapies to incorporate heart problems remedies. “By welcoming Cardior as a part of Novo Nordisk, we will strengthen our pipeline of projects in cardiovascular disease where we already have ongoing programmes across all phases of clinical development,” Novo stated in an announcement. The deal contains Cardior’s lead compound CDR132L, at the moment in section 2 scientific improvement for the therapy of coronary heart failure, Novo stated. The transaction value contains an upfront fee and extra funds if sure improvement and industrial milestones are achieved, the corporate stated, including it will fund the acquisition from monetary reserves.
#Novo #Nordisk #purchase #Cardior #Prescription drugs #billion